Virpax Pharmaceuticals announced that effective June 20, 2023, the Board of Directors of Virpax Pharmaceuticals, Inc. appointed Vinay Shah to serve as the company’s Chief Financial Officer. As Chief Financial Officer, Shah will also serve as the company’s principal financial officer and principal accounting officer. On June 18, 2023, Christopher Chipman notified the Chairman of the Board of Directors of the Company of his decision to resign from his position as the company’s Chief Financial Officer to pursue other opportunities. Chipman will remain an employee of the company until June 30, 2023 in order to aid in an orderly transition. Chipman’s resignation was not the result of any disagreement with the company on any matter relating to the company’s operations, policies, or practices, including any matters concerning the company’s controls or any financial or accounting-related matters or disclosures. “We are pleased to welcome Vinay to Virpax Pharmaceuticals. He is a seasoned executive and has extensive financial experience in the biopharmaceutical sector which we believe will be a great asset to the team,” stated Anthony P. Mack, Chairman and CEO of Virpax.
Published first on TheFly
